Peptide Initiative

Peptides · Peptide comparison

Exenatide vs Retatrutide

First-in-class GLP-1 receptor agonist derived from Gila monster venom (Byetta/Bydureon), FDA-approved for type 2 diabetes with demonstrated cardiovascular safety in the 14,752-patient EXSCEL trial and available in both twice-daily and once-weekly formulations

The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials [1][2].

  • Weight Management
  • Weight Management

At a glance

Quick comparison

Dose rangeExenatide10–10 mcgRetatrutide4–8 mg
FrequencyExenatideOnce weeklyRetatrutideOnce weekly
AdministrationExenatideSubcutaneous injectionRetatrutideSubcutaneous injection
Cycle lengthExenatideOngoing/indefiniteRetatrutide12+ weeks
Onset speedExenatideGradual (3-4 weeks)RetatrutideModerate (1-2 weeks)
Evidence levelExenatideStrong human trials (Phase 3 or FDA approved)RetatrutideModerate human trials (Phase 1-2)

Efficacy

Benefit ratings

Blood Sugar Control

Exenatide94%
RetatrutideNo recorded rating

Weight Loss

Exenatide86%
RetatrutideNo recorded rating

Heart Safety

Exenatide82%
RetatrutideNo recorded rating

Weight Loss Power

ExenatideNo recorded rating
Retatrutide98%

Metabolic Health

ExenatideNo recorded rating
Retatrutide95%

Appetite Control

ExenatideNo recorded rating
Retatrutide94%

Technical data

Compound specifications

Exenatide

Molecular formula
C184H282N50O60S
Molecular weight
4,187 Da
Half-life
Byetta: ~2.4 hours (immediate-release); Bydureon: ~7 weeks effective duration via PLGA microsphere technology; Tmax ~2.1 hours (Byetta)
Bioavailability
65–75% after subcutaneous injection (Byetta); microsphere sustained release for Bydureon
CAS number
183321-74-6

Retatrutide

Molecular formula
C221H342N46O68
Molecular weight
4731 g/mol
Half-life
~6 days (allows once-weekly dosing)
Bioavailability
High via subcutaneous injection
CAS number
2381089-83-2

Protocols

Dosing compared

Exenatide

Subcutaneous

  • 5 mcgTwice daily, within 60 minutes before the two main meals · First 1 monthFDA-labeled starting dose for immediate-release Byetta to assess tolerability before escalating [6].
  • 10 mcgTwice daily, within 60 minutes before the two main meals · OngoingFDA-labeled maintenance dose for immediate-release Byetta after 1 month at the starting dose [6].
  • 2 mgOnce weekly · Ongoing chronic therapyExtended-release exenatide (Bydureon) FDA-labeled at 2 mg once every 7 days; convenient weekly alternative to twice-daily dosing [7]. Once-weekly exenatide has cardiovascular outcome data [1].

Retatrutide

Subcutaneous

  • Weeks 1-42 mgOnce weekly · Weeks 1-4 (then escalate 2 mg every 4 weeks)Phase 2 obesity trial initiated higher-dose arms at 2 mg weekly with stepwise 2 mg increases every 4 weeks to limit GI effects [1].
  • Maintenance after titration4-8 mgOnce weekly · Maintenance after titrationMid-range maintenance doses; 8 mg produced ~22% mean weight loss at 48 weeks in the phase 2 trial [1][3].
  • Maintenance (highest studied)12 mgOnce weekly · Maintenance (highest studied)Highest studied dose; produced ~24% mean weight reduction at 48 weeks [1]. Still investigational (not FDA-approved).

Applications

Best suited for

Exenatide

Type 2 diabetes patients inadequately controlled on metformin seeking add-on therapy with weight loss benefit
Exenatide is particularly well-suited for individuals focused on type 2 diabetes patients inadequately controlled on metformin seeking add-on therapy with weight loss benefit. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
Patients preferring once-weekly dosing convenience (Bydureon 2 mg) over daily injections for improved adherence
Exenatide is particularly well-suited for individuals focused on patients preferring once-weekly dosing convenience (bydureon 2 mg) over daily injections for improved adherence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [7].
Overweight or obese type 2 diabetes patients (BMI >27) requiring glycemic control without weight gain
Exenatide is particularly well-suited for individuals focused on overweight or obese type 2 diabetes patients (bmi >27) requiring glycemic control without weight gain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [4].
Patients with established cardiovascular disease who need a GLP-1 RA with demonstrated cardiovascular safety
Exenatide is particularly well-suited for individuals focused on patients with established cardiovascular disease who need a glp-1 ra with demonstrated cardiovascular safety. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Retatrutide

Significant Obesity Management
If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs [1]. No other medication has matched this [1].
Type 2 Diabetes with Obesity
Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss [6]. The dual benefit makes it especially valuable for diabetics struggling with weight.
Metabolic Syndrome Warriors
If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously [5].
Fatty Liver Disease (MASLD)
Early research shows retatrutide may significantly reduce liver fat [7]. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.

Safety profile

Side effects

Exenatide

Common

  • Nausea
  • Vomiting and diarrhea
  • Injection site nodules (Bydureon)
  • Decreased appetite and constipation

Uncommon

  • Hypoglycemia

Serious

  • Acute pancreatitis
  • Renal impairment

Retatrutide

Common

  • Nausea
  • Diarrhea
  • Constipation
  • Decreased appetite

Uncommon

  • Increased heart rate
  • Injection site reactions

Serious

  • Pancreatitis
  • Gallbladder problems

Research status

Safety & evidence

Exenatide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Exenatide is an FDA-approved GLP-1 receptor agonist with post-market safety data spanning 15+ years, though some safety concerns have emerged. Nausea affects 30-45% of patients, [6] dose-dependent and typically improves within 1-2 weeks but can lead to treatment discontinuation in 5% of patients. Pancreatitis risk, while rare (0.1-0.2%), is increased and contraindicated in patients with history of acute pancreatitis. Benign thyroid C-cell adenomas were seen in rats across all exenatide doses in a 104-week carcinogenicity study, but this appears only in the Nonclinical Toxicology section: the immediate-release label (Byetta) carries no boxed warning and does not contraindicate medullary thyroid cancer or MEN 2. That contraindication belonged to extended-release Bydureon, which no longer has a current US label. Acute kidney injury has been reported in 0.3-1% of patients, particularly with concurrent NSAID or ACE inhibitor use. Hypoglycemia risk is minimal when used as monotherapy but increases substantially when combined with insulin or sulfonylureas.

Contraindications

  • Prior serious hypersensitivity reaction to exenatide or any excipient [6]
  • Extended-release exenatide only (Bydureon, now withdrawn in the US): personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. The immediate-release label carries no such contraindication and no boxed warning [6][7].

Retatrutide

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants [1][6]. Most side effects are gastrointestinal and tend to improve over time [3]. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing [3].

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Pregnancy or planning to become pregnant
  • History of severe pancreatitis
  • Known allergy to GLP-1 receptor agonists

Decision guide

Which is right for you?

Exenatide

Choose Exenatide if…

  • Type 2 diabetes patients inadequately controlled on metformin seeking add-on therapy with weight loss benefit
  • Patients preferring once-weekly dosing convenience (Bydureon 2 mg) over daily injections for improved adherence
  • Overweight or obese type 2 diabetes patients (BMI >27) requiring glycemic control without weight gain
  • Patients with established cardiovascular disease who need a GLP-1 RA with demonstrated cardiovascular safety

Retatrutide

Choose Retatrutide if…

  • Significant weight loss
  • Type 2 diabetes management
  • Metabolic health improvement
  • Body composition optimization